Strut Health vs Apex MD
Strut Health lists a 30-day buccal lozenge; Apex MD lists month-to-month oral semaglutide. The preparation and renewal terms matter alongside price.
Disclosure: GLP Loss is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
Strut Health
Partner
$199/mo
Semaglutide comes as a monthly injection vial or a 30-day buccal lozenge; the current oral rate is higher. Tirzepatide injection includes B6. Prescriptions renew by refill schedule, and cancellation needs at least 48 hours' notice before processing.
- Product cards distinguish the formulation and supplied period
- Prices are visible before clinical intake
- Both ingredients are offered in injectable and lozenge forms
- The FAQ describes how to pause, delay or cancel refills
- Prescription charges recur until paused or canceled
- The FAQ requires forty-eight hours of cancellation notice before processing
- The final prescription and price depend on consultation
- Medication availability and consultation requirements vary by state
Pick it for: Comparing a 30-day buccal-lozenge subscription
Not for: Anyone relying on a guaranteed one-off price or a universal no-video intake.
Apex MD
Editorial
$349/mo
Prices all four combinations: semaglutide at $299 injected and $349 orally, tirzepatide at $399 and $419. Expensive across the board, but one of the few sellers that will tell you the oral figure without an intake.
- No plan term — a month is a month
- Both molecules in both routes, each priced separately
- Prices published before the intake
- 51 jurisdictions
- Priced well above where this market sets compounded semaglutide
- The semaglutide injection contains additives with no trial behind the combination
- $50 to $100 route premium on top
- Compounding pharmacy is not named
Pick it for: Comparing month-to-month billing and the exact oral preparation
Not for: Anyone who wants the molecule on its own, or a competitive rate.
Our verdict
Apex MD lists oral semaglutide at $349 with month-to-month billing and no published multi-month rate. Strut Health lists a compounded buccal lozenge at $199 for 30 days. Its terms describe recurring prescription charges every 30 or 90 days, depending on the refill schedule, and its FAQ asks for cancellation at least 48 hours before processing. Those differences do not establish why one seller charges more or that either preparation is better. Confirm the exact formulation, supplied quantity and next charge before choosing.
What actually separates them
Strut Health and Apex MD differ on published price. The table summarizes those terms; confirm any details it does not cover with the provider.
Apex MD’s comparison figure is $150 higher than Strut Health’s — a 75% difference between the listed rates. These figures do not establish equivalent prescribed doses, supply or care. Confirm the selected product, full payment obligation and next charge.
At unchanged rates, a twelve-month illustration is about $2,388 at Strut Health against $4,188 at Apex MD — a difference of $1,800. This is not a quote for a year of care: actual charges depend on prescribed supply, purchase terms and renewals.
| Strut Health | Apex MD | |
|---|---|---|
| Published price | $199/mo | $349/mo |
What neither of them tells you
A comparison that only reports differences implies everything else is settled. Here it is not.
- Both sell a compounded drug and neither names the pharmacy that compounds it.
Before you choose either
The providers describe different service areas. Apex MD lists 2 that Strut Health does not list — AR, DC. Confirm your location and selected medication directly. A provider-wide footprint does not establish every treatment’s availability.
Whether these two publish a milligram dose is not settled in our records for both of them, so treat the two prices as not yet comparable and ask each what dose the monthly figure buys. Set the answers against every published price we hold — a lower monthly price at a smaller dose is not the cheaper option.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.